144 ·Filed May 12, 2026

MLYS

Mineralys Therapeutics, Inc.
NEUTRAL
Impact 2/10
Horizondays Processed4mo ago SEC0001964306-26-000234
Form 144 — notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine cashless exercise and sale by an officer, consistent with a pre-existing pattern of monthly option exercises. No material signal for the stock. Monitor for any acceleration in insider selling volume or unexpected insider departures.

DirectionNeutral
Confidencehigh
Horizondays
Final — all horizons settled through T+60d
MLYS ▲ +1.82% at T+60d
NEUTRAL call ✓ call won +1.82% · α vs SPY -2.61% · entry $26.86 → $27.35
Entry anchored
May 12, 03:59 PM ET
via exchange tick
T+1d
0.00%
call 0.00% · α +0.00%
$26.86
settled 5mo ago
T+5d
-3.09%
call -3.09% · α -1.93%
$26.03
settled 5mo ago
T+20d
-10.87%
call -10.87% · α -10.26%
$23.94
settled 4mo ago
T+60d
+1.82%
call +1.82% · α -2.61%
$27.35
settled 8w ago

Price Chart

Loading chart...

Executive Summary

Officer David Malcom Rodman filed a Form 144 to sell 6,348 shares of Mineralys Therapeutics (MLYS) valued at approximately $186,348 via a broker-assisted cashless exercise of employee stock options. This is a small, routine insider sale relative to the company's $2.5B market cap and follows a pattern of regular monthly sales by the same insider, making it a low-impact event.

Key Facts

  • Insider: Officer David Malcom Rodman
  • Shares to sell: 6,348 shares of common stock
  • Estimated value: ~$186,348
  • Sale method: Broker-assisted cashless exercise of employee stock options
  • Filing date: May 12, 2026
  • Prior sales by same insider: 13 transactions since Feb 2026, totaling ~$2.0M
  • Market cap: $2.5B
  • Recent insider activity (30d): 4 sells totaling $984K

Financial Impact

Proposed sale of ~$186K, representing ~0.007% of market cap

dilution

Risk Factors

  • Insider selling pattern could accelerate if stock price declines or negative news emerges
  • Cashless exercises may indicate insider needs liquidity, not necessarily bearish view

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (16 analysts)

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001964306-26-000234
Document: 0001964306-26-000234-index.html0001964306-26-000234
Document: 0001964306-26-000234.txt0001964306-26-000234
22 reports for MLYS
Performance horizon
67% Hit rate 4 of 6 directional calls best @ T+20▲ +20.97%Jun 11, 2026
Filters
Rows
Reports for MLYS — sortable, filterable
TypeNow
Aug 12, 2026
7w ago
3
NEUTRAL ★ 2/10
$26.09 $28.20▲ +8.09%▲ +9.83%$23.56 (−9.70%)
Jul 23, 2026
10w ago
Insider Cluster
NEUTRAL ★ 2/10
$26.71 $25.65▼ −3.97%▼ −7.59%$23.56 (−11.79%)
Jul 21, 2026
10w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.52 $26.61▼ −3.31%▼ −5.87%$23.56 (−14.39%)
Jul 16, 2026
11w ago
Insider Cluster
NEUTRAL ★ 3/10
$27.08 $26.09▼ −3.66%▼ −7.27%$23.56 (−13.00%)
Jun 30, 2026
13w ago
144
NEUTRAL ★ 3/10
$26.89 $26.35▼ −2.01%▲ +0.18%$23.56 (−12.38%)
Jun 29, 2026
13w ago
144
NEUTRAL ★ 3/10
$26.88 $26.71▼ −0.63%▼ −0.35%$23.56 (−12.35%)
Jun 18, 2026
15w ago
Insider Cluster
NEUTRAL ★ 2/10
$24.63 $27.08▲ +9.95%▲ +9.41%$23.56 (−4.34%)
Jun 17, 2026
15w ago
144
NEUTRAL ★ 2/10
$24.63 $27.08▲ +9.95%▲ +9.41%$23.56 (−4.34%)
Jun 11, 2026
16w ago
Institutional Cluster
BULLISH ★ 6/10
$23.94 $28.96▲ +20.97%▲ +19.08%$23.56 (−1.59%)
Jun 3, 2026
17w ago
8-K
MIXED ★ 7/10
$25.06 $27.69▲ +10.49%▲ +11.49%$23.56 (−5.99%)
Showing 10 of 22

US Market Status

Market Open — Closes in 3h 42m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access